Cell & Gene Therapy Supply Chain Software Market Expected to Grow at a 13.9% CAGR from 2024-2031 | Latest Report by InsightAce Analytic

JERSEY CITY, N.J., June 10, 2024 /PRNewswire/ — InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Cell & Gene Therapy Supply Chain Software Market Size, Share & Trends Analysis Report By Business Type (Transport, Warehouse, Distribution, Value-Added Services), Mode Of Operation (Storage, Roadways, Seaways), And End Use, Region, Market Outlook And Industry Analysis 2031”.

The Cell & Gene Therapy Supply Chain Software Market is poised for significant growth, projected to surpass USD 668.4 Mn by 2031, with a promising CAGR of 13.9% during the forecast period.
Enhanced therapies, including cell and gene therapy products, have reformed healthcare practices. The prevalence of such therapeutic options has led to an uprise shift in modern medicine’s development, production, and consumption. Moreover, such therapies have established healthcare providers to treat several rare clinical conditions.
Request for Free Sample Pages: https://www.insightaceanalytic.com/request-sample/2520 
Supply chain software in this sector encompasses solutions for inventory management, logistics, temperature monitoring, and regulatory compliance. It facilitates the coordination of multiple stakeholders, including manufacturers, contract research organizations (CROs), logistics providers, and healthcare facilities. Investments in R&D are also essential for advancing technological innovations and raising the caliber of produced goods.
Furthermore, the market’s future potential appears bright because of the growing use of digitalization. Various software solutions play crucial roles in these processes, including cell rearrangement platforms, Enterprise-manufacturing systems, inventory management systems, laboratory information management systems, logistics management systems, patient management systems, quality management systems, and tracking and tracing systems.
List of Prominent Key Players in the Cell and Gene Therapy Supply Chain Software Market:
Azenta Life SciencesBiocairBioLife SolutionsCareDxCryoportLonzaNMDP BioTherapiesTraceLinkTrakCelVeeva SystemsEmersonLabVantage SolutionsMarkenMasterControlQuickSTATSiemensStafa Cellular TherapySteinerSTEMSOFT SoftwareTECHNICALThermo Fisher ScientificOther Prominent PlayersCell and Gene Therapy Supply Chain Software Market Scope:
Report Attribute
Specifications
Market Size Value In 2023
USD 240.5 Mn
Revenue Forecast In 2031
USD 668.4 Mn
Growth Rate CAGR
CAGR of 13.9% from 2024 to 2031
Quantitative Units
Representation of revenue in US$ Mn, and CAGR from 2024 to 2031
Historic Year
2019 to 2023
Forecast Year
2024-2031
Report Coverage
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends
Segments Covered
By Process Component, Type of Software, Mode of Deployment, Type of End-User, And Scale of Operation
Regional Scope
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country Scope
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea
Order 180 Pages Full Report @  https://www.insightaceanalytic.com/buy-report/2520 
Market Dynamics:
Drivers-
Several key factors drive the Cell and Gene Therapy Supply Chain Software Market. Primarily, the rising demand for personalized medicine and advanced therapies fuels the need for efficient supply chain management solutions. Also, the complexity of cell and gene therapy manufacturing requires sophisticated software to ensure product quality and compliance with regulatory standards. In addition, the rising number of clinical trials and commercial launches of these therapies boosts demand for software that can accommodate the unique challenges of their supply chains. Lastly, the COVID-19 pandemic has underscored the importance of resilient supply chains, driving further interest in software solutions to enhance agility and visibility.
Challenges:
The Cell & Gene Therapy Supply Chain Software Market faces several challenges. The high cost of developing and implementing specialized software poses a barrier to entry for smaller companies. Also, regulatory complexities and stringent compliance requirements add layers of difficulty to software development and usage. Interoperability issues between different systems can hinder seamless data exchange and integration. Lastly, the need for continuous adaptation to evolving technologies and industry standards presents ongoing challenges for software providers and users alike, requiring constant updates and enhancements to meet the dynamic needs of the cell and gene therapy sector.
Regional Trends:
North America is a leading region in the biotechnology and pharmaceutical industries, boasting a robust ecosystem of companies specializing in cell and gene therapy research, development, and manufacturing. The region’s leading software companies and technology hubs further enhance its position. This comprehensive overview of regional trends is crucial for regulatory authorities to stay informed and make informed decisions.
Curious about this latest version of the report? @ https://www.insightaceanalytic.com/enquiry-before-buying/2520 
Recent Developments:
In January 2024, Veeva Systems partnered with SK Biopharmaceuticals to optimize the former company’s quality management system and decrease the risks involved with quality assurance of regenerative healthcare medicine.In Nov 2023, Cryoport, Inc. announced its acquisition of Tec4med LifeScience GmbH. Cryoport’s acquire of Tec4med is a significant step in broadening their range of condition monitoring solutions, fostering new product development, and accelerating European market penetration, notably in the DACH area (Germany, Austria, Switzerland).In June 2023, Biocair has integrated TrakCel’s software with OCELLOS to increase customer service, automation, and visibility in the cell and gene therapy (CGT) supply chain.TrakCel’s advanced therapeutic orchestration platform OCELLOS streamlines the cell, gene, and immunotherapy supply chain. To scale cell and gene therapy development, the platform tracks chain of identification and custody. This lets stakeholders track orders in transit.Segments of Cell and Gene Therapy Supply Chain Software Market –
By Process Component-              
Sample Collection and Processing ComponentManufacturing ComponentLogistics ComponentPatient Identification and Treatment Follow-up ComponentBy Type of Software-    
Enterprise Manufacturing System (EMS)Laboratory Information Management System (LIMS)Inventory Management System (IMS)Cell Orchestration Platform (COP)Quality Management System (QMS)Logistics Management System (LMS)Patient Management System (PMS)By Mode of Deployment-           
On-premises DeploymentCloud-based DeploymentBy Type of End-User-    
Pharmaceutical CompaniesCell Therapy LabsHospitals / Medical CentersResearch Institutes / BiobanksBy Scale of Operation- 
Clinical ScaleCommercial ScaleBy Region-
North America-
The USCanadaMexicoEurope-
GermanyThe UKFranceItalySpainRest of EuropeAsia-Pacific-
ChinaJapanIndiaSouth KoreaSoutheast AsiaRest of Asia PacificLatin America-
BrazilArgentinaRest of Latin America Middle East & Africa-
GCC CountriesSouth AfricaRest of Middle East and AfricaFor More Customization @ https://www.insightaceanalytic.com/customisation/2520 
Why should buy this report:
To receive a comprehensive analysis of the prospects for global Cell and Gene Therapy Supply Chain Software marketTo receive industry overview and future trends of global Cell and Gene Therapy Supply Chain Software marketTo analyze the Cell and Gene Therapy Supply Chain Software market drivers and challengesTo get information on the Cell and Gene Therapy Supply Chain Software market size value (US$ Mn) forecast till 2031Major Investments, Mergers & Acquisition in global Cell and Gene Therapy Supply Chain Software industryOther Related Reports Published by InsightAce Analytic:
AI in Patient Management Market 
Digital Pharmaceutical Supply Chain Management Market 
4PL Logistics Market
AI in Medical Supplies/Inventory Management Market
Patient Engagement Solutions Market
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact Us:InsightAce Analytic PVT. LTDTel.: +1 551 226 6109Email: info@insightaceanalytic.com Follow us on LinkedIn: https://www.linkedin.com/company/insightace-analytic-pvt-ltd/
Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/cell–gene-therapy-supply-chain-software-market-expected-to-grow-at-a-13-9-cagr-from-2024-2031–latest-report-by-insightace-analytic-302168224.html